Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Chief Operating Officer - 2022-11-13
Director TitleAgeSince
Director/Board Member 61 2005-08-15
Chairman 66 2014-09-18
Director/Board Member 55 2008-06-04
Change 5-day change 1-year change 3-year change Capi.($)
-23.37%-37.69% - - 1.28M
-0.71%-0.29%+56.45%+107.18% 54.92B
-1.22%+2.25%+43.78%+38.45% 44.31B
-0.41%+4.82%-14.73%-19.44% 22.96B
-1.68%-3.06%-5.49%+380.05% 21.12B
-2.91%-1.18%+7.21%-36.53% 16.31B
-2.38%-3.38%+5.53%-41.88% 15.19B
-1.22%-1.28%+25.29%+174.02% 13.32B
+1.48%+11.36%+22.59% - 12.48B
+4.10%+7.02%+104.41%+226.33% 11.21B
Average -2.83%+2.67%+27.23%+103.52% 23.54B
Weighted average by Cap. -0.81%+2.01%+31.05%+94.28%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!